The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Insmed Incorporated (NASDAQ:INSM) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like.

On April 9, 2026, Raymond James initiated coverage of Insmed Incorporated (NASDAQ:INSM) with an Outperform rating. The firm’s analyst set a price target of $200 on the stock. According to the analyst’s research note, the early launch of Brinsupri has materially de-risked the company’s trajectory. The firm described it as one of the strongest inflammation and immunology debuts ever and cited a massive underserved market and limited competition for the drug.

In a separate development, on April 14, 2026, RBC Capital raised its price target on Insmed Incorporated (NASDAQ:INSM) from $212 to $216 while maintaining an Outperform rating on the company’s stock. RBC Capital told investors that, in a survey of 50 physicians conducted by the firm, high satisfaction was noted with Brinsupri’s clinical profile. Physicians expect to significantly increase prescriptions, noting that the eligible patient population is expanding dramatically. With these findings, the analyst believes the drug’s strong growth in the immunology market is reinforced.

Druckenmiller has been one of the most aggressive accumulators of Insmed Incorporated (NASDAQ:INSM) across consecutive quarters, building it into a top-three position, while Cramer believes that the stock is worth following:

Still, this one is worth keeping an eye on.

Founded in 1988, Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company. Headquartered in New Jersey, the company specializes in pulmonary conditions, particularly those involving chronic airway inflammation and infectious diseases.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 New Contenders for S&P 500 Index and Harvard University Stock Portfolio: Top 10 Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.